Table 3.
Clinical predictors and metabolic parameters of Cox regression analysis for predicting PFS and OS
Category | End points | Variables | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|---|---|
HR | 95%CI | P | HR | 95%CI | P | |||
Clinical predictors | PFS | NCCN-IPI | 1.331 | 1.145–1.548 | < 0.001 | 1.215 | 1.021–1.445 | 0.028 |
β2-MG | 2.668 | 1.606–4.433 | < 0.001 | 1.904 | 1.060–3.421 | 0.031 | ||
OS | NCCN-IPI | 1.419 | 1.174–1.715 | < 0.001 | 1.294 | 1.041–1.607 | 0.020 | |
β2-MG | 3.015 | 1.589–5.719 | < 0.001 | 1.933 | 0.927–4.030 | 0.079 | ||
Metabolic parameters | PFS | SUVmax | 1.352 | 0.814–2.247 | 0.244 | – | – | – |
SDmax | 5.592 | 2.652–11.790 | < 0.001 | 4.758 | 2.236–10.120 | < 0.001 | ||
TMTV | 2.816 | 1.654–4.796 | < 0.001 | 2.186 | 1.275–3.750 | 0.004 | ||
OS | SUVmax | 1.664 | 0.849–3.262 | 0.138 | – | – | – | |
SDmax | 4.499 | 2.126–9.517 | < 0.001 | 3.939 | 1.832–8.469 | < 0.001 | ||
TMTV | 2.441 | 1.209–4.932 | 0.013 | 1.797 | 0.874–3.697 | 0.111 |
PFS progression-free survival, OS overall survival, NCCN-IPI National Comprehensive Cancer Network-International Prognostic Index, β2-MG β2-microglobulin, SUVmax maximum standardized uptake value, Dmax the largest distance between two lesions, SDmax standardized Dmax, TMTV total metabolic tumor volume, HR hazard ratio, CI confidence interval.